Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults 18 years or older
First advanced of diagnosis of metastatic/Stage IV) melanoma
Tested for PD-L1 expression with a tumor proportion score (TPS) greater than or equal to 1% (Phase 1 data collection)
Initiating a first line of therapy during the index period between October 1, 2015 through July 1, 2017
Medical history available for medical chart abstraction from date of diagnosis through most recent or current therapy (defined as end of data collection period)
You may not be if
Patients enrolled in a cancer treatment-related clinical trial prior to first line therapy initiation for metastatic/Stage IV) melanoma
Clareo Health | A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US
